Clinical trials: Botulinum toxin type A
Hyperhidrosis Primary Focal Axilla
Evaluate the Efficacy and Safety of MEDITOXIN in Treatment of Primary Axillary Hyperhidrosis
This study is intented to evaluate the efficacy and safety of MEDITOXIN compared to placebo in treatment of primary axillary hyperhidrosis.
- Trial name
- NCT03760198
- Testing
- Meditoxin
- Where
- South Korea
- Volunteers
- 220 people
- Sponsor
- Medy-Tox
Cerebrovascular Accident
A Multicenter, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy and Safety of GSK1358820 (Botulinum Toxin Type A) in Chinese Subjects With Post-stroke Upper Limb Spasticity
This trial is a multicenter, double-blind, randomized, placebo-controlled study to compare GSK1358820 (Botulinum Toxin Type A, also known as "OnabotulinumtoxinA" or "Botox") with placebo on the efficacy and safety of treatment in…
- Trial name
- NCT01153815
- Testing
- GSK1358820(Botulinum toxin type A)
- Where
- 13 sites in China
- Volunteers
- 170 people
- Sponsor
- GlaxoSmithKline
Injection Site Discomfort
A Controlled Study on Pain Management With Injection of Botulinum Toxin for Glabellar Line Correction
This is an open-label, single-center, randomized, split-face, controlled study to assess the effect of comfort intervention on pain during treatment injection compared against non-comfort intervention.
- Trial name
- NCT06161246
- Testing
- Vibrating Beauty Bar
- Where
- United States
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Galderma R&D
Hyperhidrosis, Residual Limbs
Topical Aluminium Chloride vs OnabotulinumtoxinA Intradermal Injections in Residual Limb Hyperhidrosis (Lower Limbs)
The aim of this study is to demonstrate onabotulinumtoxinA superiority to aluminium chloride for the treatment of residual limb hyperhidrosis.
- Trial name
- SALUTOX (NCT03433859)
- Testing
- OnabotulinumtoxinA, Topical Aluminium Chloride (cosmetic product)
- Where
- 9 sites in France
- Volunteers
- 54 people
- Sponsor
- Direction Centrale du Service de Santé des Armées
Pain
Assessing the Efficacy of Virtual Reality Analgesia (VRA) in Pediatric Patients for Pain Control
To evaluate the efficacy of virtual reality analgesia (VRA) for pediatric patients undergoing Botulinum toxin injections (BTI) for spasticity management.
- Trial name
- PEDSPAINVR (NCT03480724)
- Testing
- Google Cardboard VRA, Oculus Rift VRA
- Where
- United States
- Volunteers
- 55 people
- Sponsor
- Montefiore Medical Center
Spasticity
Botox vs. Baclofen for Upper Limb Spasticity
The purposes of this pilot study are to evaluate the safety and efficacy of Botox® compared to the safety and efficacy of oral baclofen in reducing muscle tone-related disability resulting from neurological damage or a stable…
- Trial name
- NCT00280280
- Testing
- intramuscular Botox versus oral baclofen
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- Vanderbilt University
Bladder Pain Syndrome
Comparison of the Treatment of Refractory Bladder Pain Syndrome With DMSO and DMSO With Botulinum Toxin A
The purpose of this research study is to evaluate the efficacy of intravesical botulinum A toxin and DMSO in women with bladder pain syndrome who have not responded to first-line treatments.
- Trial name
- NCT03103594
- Testing
- DMSO, Botox
- Volunteers
- 2 people
- Sponsor
- University of Pennsylvania
Glabellar Frown Lines
Subject Satisfaction With AbobutulinumtoxinA Treatment
An interventional Phase 4 study to assess subject satisfaction with abobotulinumtoxinA treatment.
- Trial name
- DREAM (NCT03687736)
- Testing
- AbobotulinumtoxinA
- Where
- 6 sites in United States
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- Galderma R&D
Cerebral Palsy, Muscle Spasticity
Effect of Botox and Vibration on Bone in Children With Cerebral Palsy
Cerebral palsy (CP) is a neuromuscular disorder that affects approximately 800,000 individuals in the U.S. An estimated 70-80% of these individuals have spasticity which affects ambulation and requires management.
- Trial name
- NCT01803464
- Testing
- Low-magnitude vibration, Botox
- Where
- 2 sites in United States
- Volunteers
- 29 people, healthy volunteers welcome
- Sponsor
- University of Delaware
Parkinson's Disease, Neurogenic Bladder
Safety and Efficacy of botulinumA Toxin (BotoxA) for Treatment of Neurogenic Bladder of Parkinson's Disease
The basic nerve deficit of Parkinson's disease (PD) leads to lower urinary tract symptoms of frequency, urgency and urge urinary incontinence. Lower urinary tract symptoms tend to occur at more advanced stages of PD.
- Conditions
- Parkinson's Disease, Neurogenic Bladder, Urinary Incontinence, Clostridium Botulinum Toxin Adverse Reaction
- Trial name
- NCT01421719
- Testing
- Cystoscopic injection of Botox into the urinary bladder
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Stanford University
Migraine Disorders
Botox Injection in Treatment of Chronic Migraine
Chronic migraine is in many cases a most disabling condition. Chronic migraine is defined as headaches for at least 15 days per month, of which 8 days have typical migraine features.
- Trial name
- NCT02259075
- Testing
- Botulinum Toxin Type A
- Where
- Norway
- Volunteers
- 10 people
- Sponsor
- Norwegian University of Science and Technology
Upper Facial Rhytides, Crow's Feet Lines
BOTOX® in the Treatment of Upper Facial Lines in Japan
This study will evaluate the safety and efficacy of BOTOX® (botulinum toxin Type A) for the treatment of upper facial lines (Crow's Feet Lines and Frown Lines).
- Conditions
- Upper Facial Rhytides, Crow's Feet Lines, Glabellar Lines, Frown Lines
- Trial name
- NCT01797094
- Testing
- botulinum toxin Type A (44U), botulinum toxin Type A (32U)
- Where
- Japan
- Volunteers
- 101 people
- Sponsor
- Allergan
Spasticity, Post-Stroke
A Multicenter, Open-label, Single Dose Study of the Safety and Efficacy of GSK1358820 (Botulinum Toxin Type A) in Chinese Subjects With Post-stroke Focal Upper Limb Spasticity
This trial is a multicenter, open-label study to evaluate the safety and efficacy of GSK1358820 for treatment in post-stroke subjects with focal wrist, finger and in some cases, thumb spasticity.
- Trial name
- NCT01205451
- Testing
- Botulinum toxin type A
- Where
- 13 sites in China
- Volunteers
- 109 people
- Sponsor
- GlaxoSmithKline
Pancreatic Carcinoma
Endoscopic Botulinum Toxin Injection in the Prevention of Postoperative Pancreatic Fistula Following Distal Pancreatectomy
This phase II trial studies the effect of botulinum toxin (Botox) in preventing postoperative pancreatic fistula after distal pancreatectomy.
- Trial name
- NCT04965311
- Testing
- Botulinum Toxin Type A
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- OHSU Knight Cancer Institute
Photoaging, Wrinkle
Same-Day Combination of VI Peel and Botox for Correction of Sun Damage, Fine Lines and Wrinkles
This study is being conducted to improve standards of care in the cosmetic treatment of sun damage, fine lines, and wrinkles. VI Peels® and Botox® have been used cosmetically to improve patient concerns as monotherapies.
- Conditions
- Photoaging, Wrinkle, Sun Damaged Skin
- Trial name
- NCT05162300
- Testing
- Same Day Intervention of VI Peel (Procedure) and Botulinum Toxin (Drug)
- Where
- United States
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Vitality Institute Medical Products
Urinary Bladder, Overactive
Efficacy and Safety of GSK1358820 in Subjects With Overactive Bladder
GSK1358820 is a botulinum neurotoxin A complex that has been approved for the treatment of overactive bladder (OAB) in several countries, however, it has not been approved for OAB treatment in Japan.
- Trial name
- NCT02820844
- Testing
- GSK1358820, Antibiotic therapy, Bladder diary
- Where
- 48 sites in Japan
- Volunteers
- 250 people
- Sponsor
- GlaxoSmithKline
Drooling
A Multi-Center Study of MYOBLOC for the Treatment of Sialorrhea in Parkinson's Disease Patients
To determine safety, tolerability and preliminary efficacy of intraglandular injections of MYOBLOC for the treatment of sialorrhea in Parkinsons' Disease patients
- Trial name
- NCT00515437
- Testing
- Botulinum Toxin Type B (Myobloc)
- Where
- 18 sites in United States
- Volunteers
- 54 people
- Sponsor
- Solstice Neurosciences, LLC, a subsidiary of US WorldMeds, LLC
Moderate to Severe Glabellar Lines
A Study to Evaluate the Efficacy and Safety of QM1114-DP for the Treatment of Moderate to Severe Glabellar Lines
This is a phase 3, multicenter, randomized, double-blind, active-controlled and placebo-controlled study to evaluate the efficacy and safety of 50 units (U) of QM1114-DP for the treatment of moderate to severe GL in male and…
- Trial name
- NCT05463965
- Testing
- QM1114-DP, OnabotulinumtoxinA
- Where
- 6 sites in China
- Volunteers
- 605 people, healthy volunteers welcome
- Sponsor
- Galderma R&D
Chronic Migraine
Study of Oral Atogepant When Added to OnabotulinumtoxinA (BOTOX) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Chronic Migraine
Migraine is characterized by attacks of throbbing, moderate or severe headache, often associated with nausea, vomiting, and/or sensitivity to light and/or sound.
- Trial name
- ATO-BOTOX (NCT05216263)
- Testing
- Atogepant
- Where
- 29 sites in United States
- Volunteers
- 75 people
- Sponsor
- AbbVie
Motor Impairments, Orthopaedic Injuries
Gait Characteristics Following a Fall
The purpose of this study is to quantify the safety degree of the patient's gait, to detect the reason for the fall and quantify the biomechanical parameters related to fall.
- Conditions
- Motor Impairments, Orthopaedic Injuries, Neurological Conditions
- Trial name
- NCT01631604
- Testing
- Walking aids and devices, Muscle/nerve injection, Corrective surgery
- Where
- Israel
- Volunteers
- healthy volunteers welcome
- Sponsor
- Hadassah Medical Organization
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.